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Background: The work of developing clinical practice guidelines began just a little more than ten years ago in
China. Up to now, there have been few studies about them.
Objectives: To review and analyze the status of Chinese clinical practice guidelines in 1997–2007.
Methods: All Chinese guidelines from 1997–2007 were collected, and made a regression analysis, and a citation
analysis for evaluating the impact of guidelines. To analyze the developing quality, the most influential guidelines
were evaluated with AGREE instrument, and each guideline was evaluated to check for any updating. In order to
analyze the objective and target population, all guidelines were classified and counted separately according to
disease/symptom center, and whether towards specialists or general practitioners.
Results: 143 guidelines were collected. An exponential function equation was established for the trend in the
number of guidelines. The immediacy index in every year was very low while the average citation rate was not.
Both the percentages of highly cited and never cited were high. For the evaluation with AGREE, only the average
score of clarity and presentation was high (89.9%); the remaining were much lower. Editorial independence scored
0. Only 27 (18.9%) of 143 guidelines, were found to be evidence-based. Only a few had ever been updated, with an
average updating interval of 5.2 years. Only 2.1% were symptom-centered, and only 4.2% were aimed at general
practitioners.
Conclusion: Much progress has been obtained for Chinese guidelines development. However, there were still
defects, and greater efforts should be made in the future.
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Clinical practice guidelines are systematically developed
statements to assist practitioner and patient decisions about
appropriate health care for specific clinical circumstances
(Institute of Medicine, 1990) [1]. They are expected to
promote more consistent, effective and efficient medical
practice and to improve health outcomes [2]. A large num-
ber of good guidelines have been produced by numerous
organizations all over the world, especially in UK, USA,
Canada, Australia and New Zealand. The work of develop-
ing guidelines began just a little more than ten years ago in
China, encouraging progress has been made. But up to* Correspondence: shqcui@163.com; cumsfmxq@ccmu.edu.cn
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reproduction in any medium, provided the ornow, there have been few studies about them, and know
very little about their status. What is their quality like? Are
they as scientific and rigorous as the international ones?
And how can we improve them. This study aims to de-
scribe the status of Chinese guidelines and to identify both
successes and defects. We hope to help promote Chinese
guidelines development, and to promote Chinese medical
practice in general.
Methods
Inclusion and exclusion criteria
(1) Only those guidelines that were developed by
authoritative academic organizations were included.
Those by individual suggestions of some specialists
were excluded.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The formulae and explanations for calculation of
the citing indices
index formula explanation for character
immediacy index = C1/A ‘C1’ means the number of
times that all the guidelines
were cited in the year when
published for the first time.
‘A’ means the total number of
guidelines in the year when
published for the first time
(the year is the same as
one of C1).
high cited rate = G1/N ‘G1’ means the number of
guidelines that were
highly cited





= G2/N ‘C2’ means the number of
cited times of all the




= C2/N ‘N’ means the number of all
the guidelines being selected
for citation analysis
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were excluded for they were not developed in China.
(3) Guidelines aimed how to use some medical
equipment or how to handle some laboratory test
were excluded.
(4) The time scope of the search was from 1997 to
2007.
Search strategy
Google Scholar, China National Knowledge Infrastruc-
ture (CNKI), Wanfang, Vip and the website of Ministry
of Health were searched for all the clinical practice
guidelines in China (1997–2007). The key words for the
searches included Chinese words for terms such as
‘guidelines’, ‘clinical’, ‘clinical practice’, ‘prevention’, ‘diag-
nosis’ ‘treatment’, and ‘management’. Chinese Medical
Citation Index (CMCI) was searched to compile the cit-
ation analysis (1997–2007).
Trend analysis of clinical guidelines
All the guidelines were recorded on an EXCEL form and
were classified by the year when they were developed. A
function equation of the number of guidelines according
to time was established using SPSS software. According
to the equation, the numbers of guidelines in 2008,
2009, and 2010 can be forecasted.
Citation analysis
CMCI, from 1997 to 2007, was searched to make the cit-
ation analysis. But not all the guidelines were collected
in it. And the search was done in 2008. Guidelines
developed after 2007 have less time to be cited. So the
number of the citation would be expected to be less.
This is a limitation of the study.
Some citing indices such as the immediacy index, the
highly cited rate, never been cited rate, and the average
citation rate were calculated separately. The formulae
and explanations of them are listed in Table 1.
For the formula of the immediacy index, the numer-
ator and denominator of the fraction are of the same
period, in this study, the year in the formula is desig-
nated a calendar year. If the same guidelines were pub-
lished in different journals, we regard them as one
guideline. We only calculated the number of times cited
in the year when the guidelines were published for the
first time.
Those guidelines which were cited more than 30 times
were regarded as highly cited guidelines.
Appraisal of the guidelines using the AGREE instrument
The highest cited guidelines (having been cited more
than 500) were further evaluated using the AGREE I in-
strument (version 2003) [3] as they had more impact on
practice. Two reviewers performed the evaluation. Bothreviewers were medical graduates and familiar with the
AGREE instrument. Neither of them was provided with
financial reimbursement for their work, and none
reported any conflict of interest.
Each of these guidelines was evaluated across six
domains including: scope and purpose, stakeholder
involvement, rigor of development, clarity and presenta-
tion, application, and editorial independence. And the
standardization of scores (percentage) of them were cal-
culated. Lastly, the average standardization of scores for
7 guidelines for every domain was calculated.
Analysis of the number of evidence-based guidelines
All the guidelines were appraised whether they met the
criterion that it is mentioned in the document about rat-
ing the quality of evidence or grading recommendation
strength or having referred to allied evidence-based
guidelines abroad in the process of guideline’s develop-
ment. The percentage of them was calculated.
Analysis of the updating of Chinese clinical guidelines
All the guidelines that had been updated were collected
and their percentage was calculated. And the average
updating interval was obtained through using the sum of
all updated interval divided by the total number of all
updated guidelines.
Analysis of objective and target population
All the guidelines were divided into disease guidelines
(disease center) and symptom guidelines (symptom
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those special for general practitioners were calculated.
Results
Collection of the guidelines
The total number of documents which were related to
guidelines was more than 400. 143 guidelines were
selected according to the selection criteria.
The increasing trend of guidelines amount in China
Some statistics for the number of Chinese guidelines in
1997–2007 were calculated, that are listed in Table 2. An
exponential function equation was obtained to describe
the trend of the guidelines’ number developed (according
to the date affixed to the guidelines document) during last
decade.
That is : F tð Þ ¼ 1:450 e0:290t:
‘F(t)’ represents the number of guidelines; ‘t’ is the
number of year (as 1 represents year of 1997, and 2
represents1998); ‘e’ is the base number of natural loga-
rithm. F value of the function equation is 48.919
(P = 0.000). R2 (Coefficient of determination) =0.845,
Adjusted R2 = 0.827, indicating a good fitting equation.
All the actual numbers of guidelines are within the
confidence interval as shown in Table 2, what further
prove the equation is a good fit.
From the function equation, the forecasted number of
guidelines in 2008, 2009, and 2010 would be 47, 63, and
84 respectively.
The Figure 1 describes the increasing trend of Chinese
clinical guidelines in 1997–2007.Table 2 Amount and citing analysis of Chinese clinical guidel
















Immediacy index is used to measure the adoption speed of guidelines. It equals C1
* No guidelines were published in 1998. (All the guidelines developed in 1998 had
in 1998.The citation analysis of clinical guidelines in China
A total of 108 guidelines were collected for the citation
analysis. The results are listed as below.
(1) Immediacy index in every year is listed in Table 2.
(2) The number of highly cited guidelines was 33
(30.6%). Among them respiratory and cardiology
medicine had the most guideline with 12 (11.1%)
and 6 (5.6%), respectively.
The three most cited guidelines were the Guidelines
for Prevention and Treatment of Bronchial Asthma
(produced in 1997)[4], the Guidelines for Diagnosis
and Treatment of Chronic Obstructive Pulmonary
Disease (COPD)[5], and the Guidelines for
Prevention and Treatment of Hypertension in China
(produced in 1999)[6]. Their citation frequencies
were 1720, 1446, and 685 respectively.
(3) 20 guidelines were never cited (18.5%).
(4) The average citation rate was 94.3. Different
disciplines had different citation rates. The highest
were respiratory medicine (429.9) and cardiology
medicine (246.1). The average citation rates of most
disciplines were between 2.5 and 86. The rates of
some disciplines were very low, even 0 or 1.
Appraisal of selected guidelines using the AGREE
instrument
The standardization of scores (percentage) of six domains
are listed in Table 3, as well as average standardization of
scores for all 7 guidelines, spearman correlation coefficients
between two reviewers and their statistic significance.
For all the domains of the seven guidelines being
appraised, only clarity and presentation scored highlyines developed in 1997- 2007
s
















/A as listed in Table 1.
not been published until 1999) So the immediacy index cannot be calculated
Figure 1 The exponential curve of Chinese clinical guidelines published between 1997 and 2007.
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scope and purpose (41.3%), stakeholder involvement
(10.1%), rigor of development (19.4%), application
(23.0%), and editorial independence (0.0%).
Editorial independence scored 0 because none of the
guidelines provided any information about this criterion, as
well as not for stakeholder involvement and applicability in
most guidelines. For the domain of stakeholder involve-
ment, only one guideline (i.e. Guidelines for Prevention and
Treatment of Hypertension in China) scored 54.2% while
two others scored 12.5% and 4.2%, the rest all 0. The aver-
age score of scope and purpose was better than other
domains (except for clarity and presentation). Of this do-
main, the item of considering benefits, side effects and risksTable 3 The scores of evaluating 7 guidelines by AGREE instr
AGREE Domain Asthma (1997)a COPDb Hyper-ten
scope and purpose (%) 16.7 27.8 66.7
stakeholder involvement (%) 4.2 0.0 54.2
rigor of development (%) 14.3 16.7 28.6
clarity and presentation (%) 95.8 95.8 100.0
Applicability (%) 16.7 27.8 50.0
editorial independence (%) 0.0 0.0 0.0
Spearman correlation coefficient 0.754 0.600 0.493
Sig.(2-tailed) <0.01 <0.01 <0.05
Note:
a. the Guidelines for Prevention and Treatment of Bronchial Asthma (produced in 1
b. the Guidelines for Diagnosis and Treatment of COPD.
c. the Guidelines for Prevention and Treatment of Hypertension in China (produced
d. the Guidelines for Diagnosis and Treatment of Acute Myocardial Infarction (AMI)
e. the Guidelines for Prevention and Treatment of Bronchial Asthma (produced in 2
f. the Guidelines for Diagnosis and Treatment of Hospital Acquired Pneumonia (HAP
g. the Guidelines for Diagnosis and Treatment of Obstructive Sleep Apnea/Hypopnescored well in most guidelines. However, there was not any
information provided in any guidelines for the items of ex-
ternal review and updating. The average score of rigor of
development was not satisfactory either (<30%). For the
criterion of selecting the evidence only one guideline scored
4, while all the others scored 1. Developers of most guide-
lines had not rigorously evaluated evidence by themselves.
The amount of evidence-based guidelines
Only 27 (18.9%) of 143 guidelines, were found to be
evidence-based. Some of them referred only to the
evidenced-based ones from abroad. The developers had not
rigorously assessed the evidence by themselves. And there
were many guidelines in which the recommendations wereument
sionc AMId Asthma (2003)e HAPf OSAHSg Average Score
55.6 16.7 72.2 33.3 41.3
12.5 0.0 0.0 0.0 10.1
45.2 14.3 2.4 14.3 19.4
83.3 83.3 75.0 95.8 89.9
16.7 22.2 11.1 16.7 23.0
0.0 0.0 0.0 0.0 0.0%
0.472 0.569 0.789 0.835






a Syndrome (OSAHS-Draft) [10].
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or Nominal Group Technique.
Updating of Chinese clinical guidelines
Only 11 guidelines had been updated. For those the up-
dating interval was between 2 and 10 years, with average
interval of 5.2 years.
Objective and target population of guidelines in China
Of all 143 guidelines, 140 (97.9%) were aimed at dis-
eases, while only three (2.1%) aimed at symptoms, and
only six (4.2%) special for general practitioners. There
were not any guidelines aimed at referral between gen-
eral practitioners and specialists.
Discussion
Search limitation
The study began 4 years ago, so the search for guidelines
is just from 1997 to 2007. After that, much time has
been used to write and edit this article. And the data has
not been updated, which can not reflect the status of
guidelines in China of the last 4 years. This is a limita-
tion of the study.
Progress of the amount of Chinese guidelines
There has been an exponential increase in the number
of Chinese guidelines during the last decade. Much pro-
gress had been made. Because the Chinese Society of
Rheumatic Disease developed many guidelines for
rheumatic disease in 2003 (t = 7), and the Chinese So-
ciety of Osteoporosis, Bone and Mineral Disease also
developed many in 2006 (t = 10), a large increase in the
number of guidelines was obtained in those two years.
The impact on medical practice of Chinese guidelines was
acceptable but not the same in all disciplines. The
adoption speed of guidelines was not rapid
The Average Citation Rate is the number of times that
all the guidelines having been cited divided by the num-
ber of all guidelines. This can reflect a journal’s influ-
ence. It is generally said that a journal has high
academic impact when the average citation rate is high.
The Immediacy Index is the number of times that all the
guidelines were cited divided by the total number of
guidelines published in the year when the guidelines
were published for the first time. The index introduced
by Garfield is used to measure the adoption speed. Good
journals and good papers will be read and adopted
quickly by many persons [11]. These two indexes were
adopted in this study to reflect Chinese guidelines’ im-
pact to some extent (not equate), as well as dissemin-
ation and utilization.
The results showed that the average citation rate of
Chinese clinical guidelines was rather high (>30). Thatmeans the guidelines impact was acceptable. But the Im-
mediacy Index of every year was low what indicated their
adoption speed was not rapid. More attention should
therefore be given to the dissemination. We can also see
the impact difference of the guidelines as well as their
quality from the uneven of these cited numbers.
It must be admitted that the citation indexes could not
completely reflect the guidelines influence as being cited
does not equal importance. And as most Chinese guide-
lines did not include references, the number of citations
of other papers used for their development has not been
calculated. These are all the limitations of this study.
Appraisals to guidelines development with the AGREE
instrument; merits and shortcomings
There are accepted guideline evaluation instruments
developed by different countries. Examples include the
IOM’s “Provisional Instrument for Assessing Clinical Prac-
tice Guidelines” (IOM instrument), the “Method for
Evaluating Research and Guidelines Evidence” (MERGE
instrument), Cluzeau et al’s “Appraisal Instrument for
Clinical Guidelines” (Cluzeau instrument), and Shaneyfelt
et al’s methodological appraisal instrument (Shaneyfelt in-
strument). Of all these instruments, a study showed that
The Cluzeau instrument was the most well developed and
had been tested and described as a reliable and valid
method of guideline evaluation [12].
Based on the Cluzeau instrument, AGREE instrument
was developed [12]. Up to now, it is the only guidelines in-
strument to have undergone extensive international valid-
ity assessment [13]. But there is a limitation that it does
not evaluate the quality of evidence, what is better covered
by GRADE, an approach to develop and present recom-
mendations for management of patients through rating
quality of evidence and grading strength of recommenda-
tion [14-16].
Many other studies using the AGREE instrument for
guideline evaluation reported the lowest scores in the ap-
plicability domain, and the highest in the scope and pur-
pose domain [17]. Contrasting to that, the result of this
study show that the lowest score is in the Editorial inde-
pendence, and the highest is in the clarity and presenta-
tion in China. This result helps recognizing the defects in
the development process of Chinese guidelines. It should
pay more attention to the domains of editorial independ-
ence in the future, so as to stakeholder involvement, and
applicability. As for items that the external review, up-
dating, evidence selecting criteria and evidence evalu-
ation should also receive more attention.
The method of developing guidelines in China is less
scientific and lags behind the international level
Evidence-based guidelines apply the principles of
evidence-based medicine to the process of guideline
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tion. This is followed by defining the eligibility criteria
for the studies. A systematic search of the literature is
then conducted and the evidence is evaluated. In devel-
oping recommendations, the likely benefits, risks, incon-
venience and costs associated with each treatment must
be considered in addition to addressing patients’ under-
lying values and preferences. The quality of the data sup-
porting the recommendations is evaluated and is
reflected in a grading system that describes the strength
of the recommendation and the quality of the supporting
evidence. This process ultimately results in the system-
atic development of recommendations that incorporate
evidence with patients’ preferences and values and indi-
cates the quality of the evidence [18].
However, in China, there have not been any criteria on
how guidelines should be developed. The method of
developing Chinese guidelines is less scientific and lags
behind the international level. From the results it can be
seen that most Chinese guidelines not with the evidence-
based method. This makes it difficult to ensure quality.
In addition, most Chinese ones have not listed references
of important evidence. The user is not therefore able to
examine the validity of the recommendations.
The interval and timeliness of Chinese guidelines’
updating
A ‘valid guideline should be up-to-date. Possible conse-
quences of using out-of-date guidelines include a clini-
cian’s use of diagnostic studies or treatments that do not
provide the best-known outcomes [19]. So a good guide-
line should have specific updating timetable. R.E. Burton
calculated that the half-life of a document in biology and
medicine is three years based on Burton-Kebler’s aging
equation for science and technology documents. Another
study also suggested that as a general rule, guidelines
should be reassessed for validity every three years [20].
Of all Chinese guidelines developed between 1997–
2007, only a few have been updated. And of them the
average updating interval is more than three years, fall-
ing short of international standards. Because the search
was done in 2008, some guidelines developed after 2004
have less time to be updated. So the number of updated
guidelines would be expected to be less. This is also a
limitation of the study.
Scope of Chinese guideline’s objective and target
population are not wide enough
There is shortage of Chinese guidelines aimed at general
practitioners and referral to specialist care. There is also
a shortage of aiming at symptoms. This is behind inter-
national levels. For instance, in the case of ‘cough’, there
is only one guidelines named “Guidelines for Cough
Diagnosis and Treatment (Draft) in China”, while thereare 24 in America. While general practice is developing
in China, more and more general practitioners require
guidelines for them, especially of referral and symptom
center. Those guidelines should be assigned a priority.
Conclusion
This study shows that from amount to quality, much
progress has been made of guidelines in China. But it
was uneven in different disciplines. There were some
problems in the development process and dissemination
which should be solved for better effect on practice. The
guidelines involving various objectives and target popu-
lation should be developed in the future to help clinical
practice.
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